SOUTH SAN FRANCISCO, Calif.
Dec. 5, 2013
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
Raul R. Rodriguez
, the company's president and chief operations officer, is scheduled to present a company overview at the Oppenheimer 24
Annual Healthcare Conference in
New York City
Wednesday, December 11th
2:10 p.m. ET
To access the live audio webcast or the subsequent archived recording, log on to
. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel ( www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has five product candidates in development: fostamatinib, an oral SYK inhibitor for ITP expected to enter Phase 3 clinical trials in the first half of 2014; R348, a topical JAK/SYK inhibitor for dry eye currently in Phase 2 clinical trials; R118, an AMPK activator entering Phase 1 in early 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio and Daiichi Sankyo.
SOURCE Rigel Pharmaceuticals, Inc.